. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » Brentuximab VedotinClinical Trials, Phase II as Topic/trendsHumansImmunoconjugates/immunologyImmunoconjugates/therapeutic useLymphoma/drug therapyLymphoma/immunologyTreatment Outcome
Substances： See more » ImmunoconjugatesBrentuximab Vedotin
Year: 2011 PMID： 21283093 DOI： 10.1038/nrd3364
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694